If you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your.
By Josh Beckerman BioNTech shares were down 3.4% after the company projected 2024 revenue of about 3 billion euros ($3.28 billion), compared with the average.
This year’s rollout marks a definitive transition to a commercial market for the vaccines, which had previously been purchased by the U.S. government..